<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640259</url>
  </required_header>
  <id_info>
    <org_study_id>ALCMI-004</org_study_id>
    <nct_id>NCT04640259</nct_id>
  </id_info>
  <brief_title>Epidemiology of Young Lung Cancer - Survey</brief_title>
  <acronym>EoYLC</acronym>
  <official_title>This is a 100% Virtual (Remote) Study (Survey, and Voluntary Blood Donation) to Explore Potential Environmental, Lifestyle and Genetic Factors That May be Associated With Driver Mutations of Young Lung Cancer in the USA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addario Lung Cancer Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Addario Lung Cancer Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 100% virtual (remote), case-case study to explore potential environmental,&#xD;
      lifestyle and genetic factors that may be associated with driver mutations of young lung&#xD;
      cancer in the U.S.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Exploratory epidemiology correlates</measure>
    <time_frame>1 month</time_frame>
    <description>Exploratory correlations between all questionnaire variables (demographic factors, medical history, smoking history, early life exposures (child and mother), residential history, occupational history, menstrual and reproductive history, diet, and physical activity.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>EGFR</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ROS1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>KRAS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC Other</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online Survey</intervention_name>
    <description>Epidemiological Survey (approx 200 questions)</description>
    <arm_group_label>ALK</arm_group_label>
    <arm_group_label>EGFR</arm_group_label>
    <arm_group_label>KRAS</arm_group_label>
    <arm_group_label>NSCLC Other</arm_group_label>
    <arm_group_label>ROS1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 250 subjects distributed with at least 50 subjects among the most common&#xD;
        driver mutation groups will be enrolled into the study:&#xD;
&#xD;
          1. EGFR (del19 and L858R) - 50 subjects&#xD;
&#xD;
          2. ROS1 - 50 subjects&#xD;
&#xD;
          3. ALK - 50 subjects&#xD;
&#xD;
          4. KRAS - 50 subjects&#xD;
&#xD;
          5. Other Groups:&#xD;
&#xD;
               1. Uncommon activating mutation for which specific targeted therapy exists (RET&#xD;
                  fusion, NTRK fusion, BRAF V600E, MET Exon14 skipping mutations, other activating&#xD;
                  EGFR mutations) - 25 subjects&#xD;
&#xD;
               2. Non-targetable other mutations (p53, NF1, ATM, PIK3CA, RB, non-V600E BRAF, NTRK&#xD;
                  mutation) or no identified mutation. - 25 subjects Subjects with more than one&#xD;
                  mutation will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 years and over; or the age of majority for their residential&#xD;
             state at the time of enrollment&#xD;
&#xD;
          2. Documentation of primary NSCLC, any stage&#xD;
&#xD;
          3. Less than 40 years of age at the time of NSCLC diagnosis&#xD;
&#xD;
          4. Documentation of testing by a CLIA certified lab for genomic drivers of lung cancer&#xD;
&#xD;
          5. Willingness to undergo all study procedure&#xD;
&#xD;
          6. Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male or female aged less than 18 years; or less than the age of majority for their&#xD;
             residential state&#xD;
&#xD;
          2. Greater than or equal to 40 years of age at the time of NSCLC diagnosis&#xD;
&#xD;
          3. No documentation of mutation testing&#xD;
&#xD;
          4. Unwilling to undergo all study procedures&#xD;
&#xD;
          5. Unable or unwilling to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Addario Lung Cancer Medical Institute</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

